From: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 4. FAB/LMB and BFM Staging Schemas for B-cell NHL
| Stratum | Disease Manifestation | |
|---|---|---|
| FAB/LMB International Study [13,14,17] | A | Completely resected stage I and abdominal stage II |
| Ba | Multiple extra-abdominal sites | |
| Nonresected stage I and II, III, IV (marrow <25% blasts, no CNS disease) | ||
| C | Mature B-cell ALL (>25% blasts in marrow) and/or CNS disease | |
| BFM Group [18] | R1 | Completely resected stage I and abdominal stage II |
| R2 | Nonresected stage I or II and stage III with LDH <500 IU/L | |
| R3 | Stage III with LDH 500–999 IU/L | |
| Stage IV, B-ALL (>25% blasts), no CNS disease, and LDH <1,000 IU/L | ||
| R4 | Stage III, IV, B-cell ALL with LDH >1,000 IU/L | |
| Any CNS disease | ||
ALL = acute lymphoblastic leukemia; BFM = Berlin-Frankfurt-Münster; CNS= central nervous system; FAB = French-American-British; LDH = lactate dehydrogenase; NHL = non-Hodgkin lymphoma.
aBased on results of the FAB-96/LMB study, a serum LDH level more than twice the upper limit of normal has been used to define a group B high-risk group in the international B-NHL study ANHL1131 (NCT01595048).[13]